Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
about
Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapyγδ T cells for cancer immunotherapy: A systematic review of clinical trialsThe role of gamma delta T cells in haematopoietic stem cell transplantationγδ T cells in cancer immunotherapyγδ T Cells in HIV Disease: Past, Present, and FutureThe Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T Cells.Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer.γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytesConcise Review: Targeting Cancer Stem Cells Using Immunologic ApproachesIn vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemiaLow-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.Sodium valproate sensitizes non-small lung cancer A549 cells to γδ T-cell-mediated killing through upregulating the expression of MICA.Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity.Immunosurveillance by human γδ T lymphocytes: the emerging role of butyrophilins.Acute lymphoblastic leukemia with aleukemic prodrome: preleukemic dynamics and possible mechanisms of immunosurveillance.Mucosal-Associated Invariant T Cells: New Insights into Antigen Recognition and Activation.Gamma-delta (γδ) T cells: friend or foe in cancer development?CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.T follicular helper cells: a potential therapeutic target in follicular lymphoma.Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression.γδ T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors.Expansion of Th1-like Vγ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.
P2860
Q26781175-F990D534-3A03-4596-B7E6-A791A88B2F2EQ27021705-D6DCA663-F477-49DB-A0EC-F77938CD39ECQ27030355-14B416EF-9A4D-4413-9016-9E48FE309524Q28068988-8F393804-4CD3-4274-85B1-20E3016FAF45Q28084822-D422B08B-2E0B-4282-A0DC-9AB0A1FA9FF8Q34741552-BE537B88-CE90-455C-B182-6839707B901BQ35506504-A44C2526-04F9-405E-A41D-5FCDEF485D88Q35634919-5C37C7ED-FC90-44E3-B01B-6E364A5E83C6Q35772708-8831D9B5-7C13-43ED-B787-BA9179F80364Q37354985-B0F42E62-335B-42B3-8E2B-28833E57CA7AQ37423895-7D4D3D25-9175-4EE3-9D2E-CC4F5C9DB97AQ37701514-4707575E-4F76-4DC0-8C1B-CDAAE9D51147Q38108353-4AEC3071-BE19-44E9-9DFF-83AEFCB25707Q38198742-F1FA76D3-F284-4CEE-B64C-2D929DF33155Q38271585-16B4F217-A0E7-486F-9F60-16192502CEF6Q38310258-7E0208E4-8E6D-4FCD-8456-C0B388EAAE9AQ38728528-24DE1591-4D7B-4270-A763-52BB5AB72DDBQ38742867-761E2778-4E2E-42C2-A15A-01787D6A457BQ38787725-E521CAD4-810B-4FC2-984B-41DD3A877C61Q38829403-0F8B7936-FD24-4C6D-9741-F60141360659Q39114878-20755B07-5913-4B55-AB73-6CEAE7D000C8Q39396311-820ED360-175C-4052-9A83-88CEAA24F1ECQ39397758-B9856C6F-2162-438D-BA8A-BD516FC506B2Q42344559-92E5AF14-C7CC-4264-85FD-2507C26533D9Q47133613-4F21A199-9ECB-4ED4-BCF1-A02A14B1C6B2Q47742552-B9FEFAFC-A98D-44A0-BF36-4752432B7F0AQ48124547-6D2D0510-435A-49D6-B995-3FF0F630B2B2Q48359042-2DC8387E-EBB2-4519-9A24-DE4D8756F766Q49702451-AA07049A-86B1-479C-BB26-AD59A218B3BEQ52597632-343AE9A9-8945-4E9E-BF39-F4FF8D439B31Q52649705-84642710-C8EC-4FFA-A55E-E7EAEBF5CD94Q52838659-0A561D04-47A6-4038-BD5F-99A78CA3759D
P2860
Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
@en
type
label
Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
@en
prefLabel
Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
@en
P2860
P356
P1476
Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
@en
P2093
Bernard Klein
Mounia S Braza
P2860
P304
P356
10.1111/BJH.12090
P407
P577
2012-10-15T00:00:00Z